$SAGE
Sage Therapeutics, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018027097 Filed on November 06, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $53.69M $16.10M
YoY Change 233.5% 78.89%
% of Gross Profit
Research & Development $75.05M $58.29M
YoY Change 28.77% 100.47%
% of Gross Profit
Depreciation & Amortization $300.0K $100.0K
YoY Change 200.0% 0.0%
% of Gross Profit
Operating Expenses $128.7M $74.37M
YoY Change 73.11% 95.39%
Operating Profit -$128.7M -$74.37M
YoY Change 73.11% 95.39%
Interest Expense $5.817M $677.0K
YoY Change 759.23% 146.18%
% of Operating Profit
Other Income/Expense, Net $10.00K -$23.00K
YoY Change -143.48% 228.57%
Pretax Income -$122.9M -$73.70M
YoY Change 66.76% 94.97%
Income Tax
% Of Pretax Income
Net Earnings -$122.9M -$73.72M
YoY Change 66.74% 95.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.632M -$1.965M
COMMON SHARES
Basic Shares Outstanding 46.71M 37.47M
Diluted Shares Outstanding 46.71M 37.47M

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.023B $243.5M
YoY Change 320.34% -43.55%
Cash & Equivalents $255.0M $134.9M
Short-Term Investments $768.3M $108.5M
Other Short-Term Assets $18.50M $4.900M
YoY Change 277.55% 44.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.040B $248.3M
YoY Change 318.74% -42.87%
LONG-TERM ASSETS
Property, Plant & Equipment $5.200M $1.893M
YoY Change 174.7% 89.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.900M $800.0K
YoY Change 137.5% 33.33%
Total Long-Term Assets $7.100M $2.742M
YoY Change 158.94% 71.38%
TOTAL ASSETS
Total Short-Term Assets $1.040B $248.3M
Total Long-Term Assets $7.100M $2.742M
Total Assets $1.047B $251.1M
YoY Change 316.99% -42.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.900M $13.03M
YoY Change -54.72% 150.58%
Accrued Expenses $13.20M $36.81M
YoY Change -64.14% 1126.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $54.50M $49.84M
YoY Change 9.36% 123.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.000M $1.196M
YoY Change 234.45% 498.0%
Total Long-Term Liabilities $4.000M $1.196M
YoY Change 234.45% 498.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.50M $49.84M
Total Long-Term Liabilities $4.000M $1.196M
Total Liabilities $58.50M $51.03M
YoY Change 14.63% 125.81%
SHAREHOLDERS EQUITY
Retained Earnings -$804.9M
YoY Change
Common Stock $1.794B $4.000K
YoY Change 44847625.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $988.5M $200.1M
YoY Change
Total Liabilities & Shareholders Equity $1.047B $251.1M
YoY Change 316.99% -42.45%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$122.9M -$73.72M
YoY Change 66.74% 95.04%
Depreciation, Depletion And Amortization $300.0K $100.0K
YoY Change 200.0% 0.0%
Cash From Operating Activities -$80.20M -$46.10M
YoY Change 73.97% 49.68%
INVESTING ACTIVITIES
Capital Expenditures -$1.000M -$300.0K
YoY Change 233.33% 200.0%
Acquisitions
YoY Change
Other Investing Activities $1.100M $44.10M
YoY Change -97.51% -259.21%
Cash From Investing Activities $0.00 $43.90M
YoY Change -100.0% -258.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.000M 3.700M
YoY Change 116.22% -98.05%
NET CHANGE
Cash From Operating Activities -80.20M -46.10M
Cash From Investing Activities 0.000 43.90M
Cash From Financing Activities 8.000M 3.700M
Net Change In Cash -72.20M 1.500M
YoY Change -4913.33% -98.86%
FREE CASH FLOW
Cash From Operating Activities -$80.20M -$46.10M
Capital Expenditures -$1.000M -$300.0K
Free Cash Flow -$79.20M -$45.80M
YoY Change 72.93% 49.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
211000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1793909000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-804941000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-257000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
988505000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1046999000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Assets
Assets
529937000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9350000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
42601000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51951000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2511000
CY2017Q4 us-gaap Liabilities
Liabilities
54462000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2017Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
113000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1066059000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-590447000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-228000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-128745000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46832103
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46830589
us-gaap Operating Expenses
OperatingExpenses
202706000
CY2018Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1514
us-gaap Revenues
Revenues
90000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-229011000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
us-gaap Operating Income Loss
OperatingIncomeLoss
-202706000
CY2017Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5817000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:CollaborativeArrangementMember
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
677000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75052000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14483000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58286000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2056000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
34000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
125709000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43320000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
128745000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-73719000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
74373000
us-gaap Operating Expenses
OperatingExpenses
319011000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-122918000
us-gaap Net Income Loss
NetIncomeLoss
-214494000
us-gaap Net Income Loss
NetIncomeLoss
-200698000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.63
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.37
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46706770
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37470912
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45866676
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37367802
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-112000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-74373000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
49000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
57000
us-gaap Depreciation
Depreciation
396000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
221000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
14312000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-158893000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-160378000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
214436000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93816000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
120064000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6998000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
904000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
340000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
631494000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6998000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33316000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135765000
sage Capital Expenditures Incurred Financed By Landlord Tenant Incentive But Not Yet Paid
CapitalExpendituresIncurredFinancedByLandlordTenantIncentiveButNotYetPaid
353000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
52000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-112000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-228000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
87000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123030000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73667000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-214722000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-200611000
us-gaap Profit Loss
ProfitLoss
-214494000
us-gaap Profit Loss
ProfitLoss
-200698000
us-gaap Share Based Compensation
ShareBasedCompensation
70323000
us-gaap Share Based Compensation
ShareBasedCompensation
25289000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
165000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
6901000
us-gaap Depreciation
Depreciation
780000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12271000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3370000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7205000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
724132000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1272959000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2052000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-550879000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
27480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
657730000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52042000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
307084000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
169081000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
255042000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2018Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
253123000
CY2018Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
768278000
CY2018Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1021401000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
306235000
CY2017Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
212613000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
518848000
CY2018Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2017Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
768535000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
70000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
327000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
768278000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
212642000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
212613000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7021000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5086000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1853000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1073000
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2018Q3 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
23364000
CY2017Q4 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
23473000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13001000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15838000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12110000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3166000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
172000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
124000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1572000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6657000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
6784000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6913000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
7106000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
12189000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
41221000
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4058822
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
85.00
CY2017Q4 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
325800000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4032012
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10001048
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2422437
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25478000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9731000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70323000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25289000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
113.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.43
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46706770
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37470912
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45866676
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37367802
CY2018Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46706770
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37470912
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45866676
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37367802
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6416456
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5296525
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6416456
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5296525

Files In Submission

Name View Source Status
0001564590-18-027097-index-headers.html Edgar Link pending
0001564590-18-027097-index.html Edgar Link pending
0001564590-18-027097.txt Edgar Link pending
0001564590-18-027097-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ganbgk23qefc000001.jpg Edgar Link pending
ganbgk23qefc000008.jpg Edgar Link pending
ganbgk23qefc000010.jpg Edgar Link pending
ganbgk23qefc000012.jpg Edgar Link pending
ganbgk23qefc000014.jpg Edgar Link pending
gywh2c4r0lj5000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-10q_20180930.htm Edgar Link pending
sage-20180930.xml Edgar Link completed
sage-20180930.xsd Edgar Link pending
sage-20180930_cal.xml Edgar Link unprocessable
sage-20180930_def.xml Edgar Link unprocessable
sage-20180930_lab.xml Edgar Link unprocessable
sage-20180930_pre.xml Edgar Link unprocessable
sage-ex101_388.htm Edgar Link pending
sage-ex102_111.htm Edgar Link pending
sage-ex103_112.htm Edgar Link pending
sage-ex311_6.htm Edgar Link pending
sage-ex312_7.htm Edgar Link pending
sage-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending